Eleusis is a private life sciences company that studies and develops psychedelic drugs for therapeutic use. They accomplish this by understanding how to mitigate and manage their psychoactivity. One of their main areas of focus is the therapeutic use of psychedelic drugs in chronic inflammation.1
Recently, Eleusis completed a phase I clinical trial exploring the safety and tolerability of using LSD (lysergic acid diethylamide) in conjunction with therapy for treating Alzheimer’s disease.2
Eleusis was founded by Shlomi Raz who servers as Chairman and CEO. Dr. Charles D. Nichols, Professor of Pharmacology at the Louisiana State University Science Center, is Lead Scientist at Eleusis. Dr. Nichols pioneered research into the role of serotonin 5-HT2A receptors in chronic inflammation.3,4
Support Scientific Progress
Psychedelic Science Review is working to bring cutting-edge science in the field of psychedelics to the public in the most accessible, thorough and accurate way possible. Join our communities on Facebook, Twitter, LinkedIn and Instagram and share our content with your network to help us bring scientifically-backed information about psychedelics to the world.